Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Zytiga

J&J’s prostate cancer drug approved in EU

Johnson & Johnson’s prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.

The decision was expected after European regulators endorsed the treatment in July. J&J’s Janssen unit has European… J&J’s prostate cancer drug approved in EU   



Zytiga, Prostate Cancer Drug, Improves Survival: Study

Johnson & Johnson’s drug for advanced prostate cancer, Zytiga, was deemed so beneficial in patients who had not received chemotherapy that safety advisors said those in the placebo group of a late stage trial should be offered the treatment, the company said

The unanimous recommendation by independent safety monitors was based on improvements in… Zytiga, Prostate Cancer Drug, Improves Survival: Study   



Zytiga Prednisone Combo Metastatic Castration-Resistant Prostate Cancer Trial Unblinded

A new statement by Janssen Research & Development, LLC informs that they have unblinded the Phase 3 study, COU-AA-302, which shows that Zytiga (abiraterone acetate), when taken alongside prednisone, is effective in treating mildly symptomatic or asymptomatic patients who are suffering from metastatic castration-resistant prostate cancer (CRPC) and have not gone through chemotherapy. … Zytiga Prednisone Combo Metastatic Castration-Resistant Prostate Cancer Trial Unblinded   



For advanced prostate cancer, new drug slows disease

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

The study is the first randomized… For advanced prostate cancer, new drug slows disease   



Drug slows advanced prostate cancer: study

A drug that is already approved for prostate cancer has been shown to slow the spread of advanced forms of the disease for the first time, according to research released Saturday.

Zytiga, made by Johnson and Johnson, is being tested in a randomized phase III trial involving 1,088 men with prostate cancer at 151… Drug slows advanced prostate cancer: study   



liver transplant1 - immunologic mechanisms1 - external sphincter dyssynergia1 - obstructive pyelonephritis1 - iliococcygeus1 - urgency7 - low blood potassium1 - renal anemia1 - cryotherapy1 - mental health1 - green k1 - laparoscopic nephrectomy1 - kidney failure37 - urological diseases1 - c-reactive protein1 - infections1 - prostate cancer incidence1 - nephrosis1 - prostate screening3 - alkalinizing ph agents1 - vitamin d1 - adrenocortical carcinoma1 - acute kidney injury biomarker1 - yervoy1 - testosterone therapy1 - nephrogenesis1 - stanford university school of medicine2 - hyperglycemia1 - kidney research1 - postvoid dribbling2 -